Rob Manguso

Super excited to share our latest work with @MarcelaMaus , out this week in @Nature. We show that in vivo CRISPR screens can identify genes that enhance the efficacy of CAR T cell therapy. Brief explainer below! @MGBResearchNews @broadinstitute rdcu.be/eHZG4

Overall, we help inform the development of new immune-based therapies targeting HNSCC. At the advanced stage this is a deadly cancer that is poorly responsive to current immunotherapy approaches.

Interestingly, we find that deletion of Col17a1 alone (just 1 gene regulated by UCHL5) does enhance ICB response, although not to the same degree. Further, Col17a1 overexpression can reverse the ICB sensitivity seen in UCHL5 KO tumors.

Our latest work on IO target discovery is out this week. Amazing collaboration with @DrUppaluri and led by Cong Fu. We performed in vivo CRISPR screens in #HNSCC to identify targets to enhance ICB response. @MGHCancerCenter @broadinstitute @DanaFarber nature.com/articles/s4146…

Congrats to DrCongFu ! Wonderful to collaborate with @MangusoLab on in vivo CRISPR of epigenetic targets study in #HNSCC models @NatureComms @kathleenbyates @IOTNmoonshot Thanks also to @SilvioGutkind @rsaddawi !! nature.com/articles/s4146…

@MarcelaMaus @Nature @MGBResearchNews @broadinstitute nature.com/articles/s4158…

Super excited to share our latest work with @MarcelaMaus , out this week in @Nature. We show that in vivo CRISPR screens can identify genes that enhance the efficacy of CAR T cell therapy. Brief explainer below! @MGBResearchNews @broadinstitute rdcu.be/eHZG4

Congrats to Nelson Knudsen, @escobar_giulia, @FpkMd, and the entire team for the publication of their amazing work! And thanks for @MGHCancerCenter and @broadinstitute for the support!

Obviously this is a super exciting and fast moving space with all the great work coming out this week. We're happy to be helping to advance our understanding of therapeutic T cell biology, and there will be more to come!